
### ü´Å Pulmonary Medicine: Step-Up Therapy for Mild Persistent Asthma

#### ‚úÖ True Statements
1. Patients with **asthma** who require a **short-acting Œ≤2-agonist (SABA)** more than **twice per week** but less than **4‚Äì5 times per week** for symptom control are **uncontrolled**.
2. Patients with uncontrolled mild persistent **asthma** should be stepped up to **as-needed low-dose inhaled glucocorticoid‚Äìformoterol** as the **controller and reliever**.
3. **Inhaler technique** should be confirmed at initiation of asthma therapy and **reviewed regularly**.
4. **Short-acting anticholinergic** therapy (for example, **ipratropium**) is **less effective than Œ≤2-agonists** and is **adjunctive** only for **acute exacerbations**.
5. **Leukotriene‚Äëreceptor antagonists (LTRAs)** such as **montelukast** are **not preferred first‚Äëline controller therapy** for asthma.
6. **LTRAs** may be useful in **aspirin‚Äëexacerbated respiratory disease** and for **exercise‚Äëinduced bronchospasm** prevention.
7. **Long‚Äëacting Œ≤2‚Äëagonist (LABA) monotherapy** (for example, **salmeterol alone**) is **not appropriate** in asthma.
8. **LABA therapy alone** is **not recommended** in asthma because of **increased risk for asthma‚Äërelated death**.

#### üí¨ Extra
1. The **Global Initiative for Asthma (GINA) 2024** step‚Äëup preference at this symptom frequency is **as‚Äëneeded low‚Äëdose inhaled glucocorticoid‚Äìformoterol**.
6. LTRAs can reduce **exercise‚Äëinduced symptoms**, but combination **inhaled glucocorticoid‚Äìformoterol** remains preferred for control.

#### üè∑Ô∏è Tags
#PulmonaryMedicine #Asthma #AmbulatoryCare #StepUpTherapy #InhaledGlucocorticoid #Formoterol #SABA #LABA #LTRA

#### üìö Reference
Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention 2024. Available at https://ginasthma.org/2024-report/. Accessed May 27, 2024.

#### üÜî Question ID
PMQQQ24006

#### üïí Last Updated
February 2025

---

#### üìñ Related Text
MKSAP¬†19: Pulmonary Medicine ‚Äî Airways Disease, Asthma, Management of Chronic Asthma

---

### üìò Related Text Derivations

#### ‚úÖ True Statements ‚Äî Management of Chronic Asthma
1. **Longitudinal asthma management goals** are to **control chronic symptoms**, **prevent exacerbations**, and **minimize risk of persistent airway obstruction**.
2. Asthma care uses a **stepwise approach** based on **severity assessment**, **ongoing symptom control**, and **therapy modification**.
3. **Asthma Control Test** and **Asthma Control Questionnaire** can distinguish **well‚Äëcontrolled** from **inadequately controlled** asthma.
4. Patients with **daytime symptoms <2 times weekly** and **nocturnal symptoms <2 times monthly** in the prior 4 weeks are **well controlled**.
5. **All patients with asthma** should have **quick‚Äërelief medication** available **as needed**.
6. **Inhaled glucocorticoids** are the **most effective controller medications** for asthma.
7. **Inhaled glucocorticoids** reduce **airway mucosal edema**, **mucus hypersecretion**, and **airway inflammation**.
8. In **active smokers**, higher **inhaled glucocorticoid** doses may be required because effectiveness is **diminished**.
9. **LABAs** should be used **only with inhaled glucocorticoids** because **LABA monotherapy** increases **asthma‚Äërelated death** risk.
10. **Single‚Äëinhaler** inhaled glucocorticoid‚ÄìLABA therapy is preferred to separate inhalers owing to **adherence** and **cost** advantages.
11. **Tiotropium (LAMA)** improves **lung function** and **reduces exacerbations** when added for **asthma uncontrolled** with inhaled glucocorticoid + LABA.
12. **Oral glucocorticoids** are important for **acute exacerbations**, but **long‚Äëterm use should be avoided** because of systemic adverse effects.
13. **Biologic therapies** (for example, **omalizumab**, **mepolizumab**, **reslizumab**, **benralizumab**, **dupilumab**, **tezepelumab**) are options for **severe asthma not controlled** on standard therapy.
14. **Omalizumab** reduces **exacerbations** and **emergency department visits** in **moderate to severe atopic asthma**.
15. Before biologic therapy, clinicians should verify **medication adherence**, **inhaler technique**, and **comorbidity management**.
16. **Nonpharmacologic therapy** includes **trigger avoidance/allergen management**, **tobacco smoke reduction**, **healthy diet**, and **exercise/weight loss**.
17. **Bronchial thermoplasty** may reduce exacerbations and improve quality of life in selected patients with **severe, poorly controlled asthma** and **FEV‚ÇÅ >60% predicted**.

#### üí¨ Extra
6. Benefits of inhaled glucocorticoids outweigh risks at usual doses; pneumonia risk rises mainly at **high‚Äëdose/high‚Äëpotency** formulations.
14. **Type 2 inflammation** phenotyping uses **IgE** and **eosinophil** markers to select biologics.

#### üè∑Ô∏è Tags
#Asthma #StepwiseTherapy #AsthmaControl #InhaledGlucocorticoids #LABA #LAMA #Biologics #Omalizumab #Dupilumab #Tezepelumab #NonpharmacologicTherapy

---

#### üñºÔ∏è Supplemental Figures
<figure>
  <img src="National Asthma Education and Prevention Program Guidelines on Asthma Management.png" alt="National Asthma Education and Prevention Program (NAEPP) 2020 Asthma Management Guidelines">
  <figcaption>
    2020 guidelines from the National Asthma Education and Prevention Program recommend that all adults and adolescents with mild persistent asthma use a daily inhaled glucocorticoid with an as-needed short-acting Œ≤2-agonist (SABA) or use both on an as-needed basis. Those with moderate persistent asthma should use a single inhaler with glucocorticoids and formoterol daily plus additional doses of the combination regimen as needed (known as single maintenance and reliever therapy, or SMART). For step-up therapy, daily medium- to high-dose inhaled glucocorticoids and a long-acting Œ≤2-agonist plus long-acting muscarinic antagonist and SABA as needed should be used.<br>
    <em>EIB = exercise-induced bronchospasm; ICS = inhaled corticosteroid (glucocorticoid); IL = interleukin; LABA = long-acting Œ≤2-agonist; LAMA = long-acting muscarinic antagonist; LTRA = leukotriene receptor antagonist; SABA = short-acting Œ≤2-agonist.</em><br>
    <em>National Heart, Lung, and Blood Institute. 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. National Institutes of Health; December 2020:28. NIH publication 20-HL-8140. www.nhlbi.nih.gov/health-topics/all-publications-and-resources/2020-focused-updates-asthma-management-guidelines. Accessed January 8, 2025.</em>
  </figcaption>
</figure>

---

#### üóæ Supplemental Tables


<!-- GINA Guidelines for Starting Treatment in Adults and Adolescents with a Diagnosis of Asthma -->
<table>
  <caption>GINA Guidelines for Starting Treatment in Adults and Adolescents with a Diagnosis of Asthma</caption>
  <thead>
    <tr>
      <th></th>
      <th>Step 1</th>
      <th>Step 2</th>
      <th>Step 3</th>
      <th>Step 4</th>
      <th>Step 5</th>
    </tr>
  </thead>
  <tbody>
    <!-- Track 1 -->
    <tr>
      <td>Track 1 (preferred controller and reliever)</td>
      <td>Symptoms &lt;4‚Äì5 d/wk</td>
      <td>Symptoms &lt;4‚Äì5 d/wk</td>
      <td>Symptoms most days or waking with asthma ‚â• once/wk</td>
      <td>Daily symptoms, or waking with asthma ‚â• once/wk, and low lung function</td>
      <td>‚Äî</td>
    </tr>
    <tr>
      <td>Controller regimen</td>
      <td>As-needed low-dose ICS-formoterol</td>
      <td>As-needed low-dose ICS-formoterol</td>
      <td>Low-dose maintenance ICS-formoterol</td>
      <td>Medium-dose maintenance ICS-formoterol</td>
      <td>Add on LAMA<br>Assess phenotype<br>Consider high-dose maintenance ICS-formoterol +/‚àí anti-IgE, anti-IL5/5R, anti-IL4RŒ±, anti-TSLP</td>
    </tr>
    <tr>
      <td>Reliever</td>
      <td colspan="5">As-needed low-dose ICS-formoterol</td>
    </tr>
    <!-- Track 2 -->
    <tr>
      <td>Track 2 (alternative controller and reliever)</td>
      <td>Symptoms &lt; twice/mo</td>
      <td>Symptoms ‚â• twice/mo but &lt;4‚Äì5 d/wk</td>
      <td>Symptoms most days or waking with asthma ‚â• once/wk</td>
      <td>Daily symptoms, or waking with asthma ‚â• once/wk, and low lung function</td>
      <td>‚Äî</td>
    </tr>
    <tr>
      <td>Controller regimen</td>
      <td>Take ICS whenever SABA taken</td>
      <td>Low-dose maintenance ICS</td>
      <td>Low-dose maintenance ICS-LABA</td>
      <td>Medium/high-dose maintenance ICS-LABA</td>
      <td>Add on LAMA<br>Assess phenotype<br>Consider high-dose maintenance ICS-LABA +/‚àí anti-IgE, anti-IL5/5R, anti-IL4RŒ±, anti-TSLP</td>
    </tr>
    <tr>
      <td>Reliever</td>
      <td colspan="5">As-needed ICS-SABA or as-needed SABA</td>
    </tr>
  </tbody>
</table>
<p><em>Anti-TSLP = thymic stromal lymphopoietin; ICS = inhaled corticosteroid (glucocorticoid); IL = interleukin; LABA = long-acting Œ≤‚ÇÇ-agonist; LAMA = long-acting muscarinic antagonist; SABA = short-acting Œ≤‚ÇÇ-agonist.</em></p>
<p><em>Information from Global Initiative for Asthma. Global strategy for asthma management and prevention. Updated 2024. https://ginasthma.org/2024-report/. Accessed November 21, 2024.</em></p>

#### ‚úÖ True Statements (derived from the table)
1. **Albuterol** can cause **tachycardia** and **hypokalemia**.  
2. **Levalbuterol** should **not** be used as **monotherapy in asthma**.  
3. **Ipratropium bromide** may cause **dry mouth**, **tachycardia**, and rarely **acute narrow-angle glaucoma**.  
4. **Albuterol/ipratropium** combinations produce the **combined adverse effects** of both drug classes.  
5. **Long-acting Œ≤2-agonists (LABAs)** (for example, **formoterol**, **salmeterol**, **arformoterol**, **olodaterol**, **indacaterol**) carry a **boxed warning against monotherapy in asthma**.  
6. **Long-acting muscarinic antagonists (LAMAs)** (for example, **tiotropium**) can cause **dry mouth**, **tachycardia**, **urinary retention**, and rarely **acute narrow-angle glaucoma**.  
7. **Inhaled glucocorticoids** (for example, **beclomethasone**, **budesonide**, **fluticasone**) can cause **dysphonia**, **xerostomia**, **oral candidiasis**, **bruising**, and **pneumonia**, with systemic effects uncommon at inhaled doses.  
8. **Oral glucocorticoids** (for example, **prednisone**, **prednisolone**, **methylprednisolone**) can cause **adrenal suppression**, **osteoporosis**, **glaucoma**, **diabetes mellitus**, **opportunistic infection**, **insomnia**, **cataracts**, **hypertension**, **weight gain**, **myopathy**, and **acne**.  
9. **Leukotriene-modifying agents** (for example, **montelukast**) may cause **headache**, **liver disease** (rare), or **neuropsychiatric events** including **suicidal ideation**.  
10. **Theophylline** overdose can be **fatal** and is associated with **tachycardia** and **nausea**.  